Prostate cancer study of CRT + Upfront ADT vs. PHPC + Salvage ADT

Official Title

A Randomized Phase II Study of the Clinical and Metabolic Effects Of Conventional RT with Upfront ADT vs Escalated Dose Hypofractionated RT With Prompt ADT Salvage in High-Risk Prostate Cancer


The proposed study will examine the clinical and metabolic implications of using escalated dose hypofractionated RT with prompt ADT salvage in comparison to upfront ADT with conventional RT.

Primary endpoints:

  • Development of hormone refractory prostate cancer.
  • Changes in metabolic and body composition parameters.

Secondary endpoints:

  • Biochemical failure.
  • Overall survival.
  • Radiation Toxicity

Trial Description

Patients with high risk prostate cancer will be randomized to receive either conventional therapy (conventional RT + upfront ADT) or the investigational therapy (hypofractionated RT + prompt ADT salvage). Patients will be evaluated for acute radiation treatment related toxicities at each visit throughout the treatment period as well as at 6 weeks following the end of treatment.

Patients will continue to be followed at the Cancer Centre in accordance with standard clinical practice as follows:

  • PSA testing conducted every 3 months thereafter for 5 years
  • Follow-up visits in the clinic at 6 months following the 6 week post end of treatment visit and every 6 months thereafter until 5 years from the start of treatment.

In addition, metabolic evaluations will be conducted at the University of Waterloo at the end of treatment and at 6 months following the 6 week post end of treatment visit.

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society